🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

BEAT-PCD are launching a new biobank project 'complete:PCD'. If you see patients with PCD and are interested to receive more information or to take part please complete this short survey forms.office.com/e/58eLYJeqed

Lessons in Bronchiectasis Webinar Series ersnet-org.zoom.us/webinar/regist… Register for this free webinar brought to you by EMBARC. On 20.03.24, Prof Michal Shteinberg will be joined by Dr Eva Polverino to discuss "Bronchiectasis plus: the association of BE and other airway diseases"

In celebration of World #Asthma Day 2024, GINA has selected the theme of “Asthma Education Empowers”. GINA emphasizes the need to empower people with asthma with the appropriate education to manage their disease, and to recognize when to seek medical help. ginasthma.org/world-asthma-d…

Results of the open label TAPIR trial: glucocorticoid discontinuation in GPA #ANCA vasculitis. ▶️ higher number of relapse at 6 months for the discontinuation group ▶️ but driven by minor relapses and by subgroup not treated but Rituximab. Peter Merkel #vasculitisBCN2024

🔥🔥Rhinitis phenotypes based on multimorbidities ▶️bit.ly/4dj9v7x

Julia, de la asociación @sevillarespira_, cuenta su experiencia siendo paciente de asma grave durante la adolescencia. ¿Fuisteis adolescentes con asma o tenéis un/a hij@ en esta situación? 🤔

¿Conoces lo que es el Déficit de Alfa-1-Antitripsina? Una rara condición genética que puede provocar afectación pulmonar y hepática. El diagnóstico precoz y evitar el tabaquismo es el papel clave para evitarla. #Neumosur #EPOC #Alfa1Antitripsina #SaludRespiratoria

Día Mundial del Asma 2024...LA EDUCACIÓN SOBRE ASMA EMPODERA.

Despite the amazing advances in severe asthma, there remain big challenges for patients without evidence of T2 inflammation A new review from the ERJ ERS publications discusses the challenges and emerging treatment strategies for non-Type 2 severe asthma erj.ersjournals.com/content/erj/ea…

Original Article: Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation (NOTUS phase 3 trial) nej.md/4dF7N06 #Pulmonology

Ask us your questions about bronchiectasis, particularly about current and future treatment. We will then answer these questions live in our Bronchiectasis Question Time webinar on 1 July. Find out more: europeanlung.org/en/get-involve… #WorldBronchiectasisDay

Our automated Bronchus-Artery analysis has been used to assess bronchus and artery dimensions and ratios throughout the airway tree in this study on PCD, showing the ability of automated BA analysis to successfully identify BA pairs on chest CT. atsjournals.org/doi/10.1164/aj…

Its World Bronchiectasis Day 2024! Today we raise awareness of bronchiectasis as a COMMON and NEGLECTED chronic respiratory condition in urgent need of new treatments. World Bronchiectasis is an initiative shared by Lung Health Organisations, Societies and Charities worldwide

Today is #WorldBronchiectasisDay! We think patients deserve to be informed about their lung condition. Our information hub is full of useful resources on bronchiectasis, available in several languages. Learn more: europeanlung.org/en/information…

**hot off the press** positive outcome in the phase II Airleaf trial and plans for phase III trial. Further wonderful news for bronchiectasis patients. Lena Group Respiratory Hub 🫁 Boehringer Ingelheim James D Chalmers #WBConf2024

[#WBConf24 ] the PCD parallel track is starting after an introduction from BEAT-PCD (ERS CRC) chairs Amelia Shoemark and Myrona Goutaki

Truly fantastic 3 days at #WBConf24 discussing science and meeting team #bronchiectasis friends worldwide. Massive thanks to James D Chalmers Stefano Aliberti Francesco Blasi Amelia Shoemark Lena Group Respiratory Hub 🫁 and the brilliant #Dundee team! P.S. ASPEN results were cool!

The phase 3 ASPEN trial enrolled adults with bronchiectasis and a history of exacerbations. This paper outlines the trial design, and reveals that baseline characteristics and treatment patterns were representative of a global bronchiectasis population. bit.ly/3vu7RyR

Common causes of coughing include viral upper respiratory infections, lung disease, heart failure, reflux, side effects of medications or exposure to irritants. Chronic #cough syndrome refers to a cough that persists for 6 weeks or longer. #asthma aaaai.org/tools-for-the-…

🎉🌍 Today is the first-ever World Chronic Cough Awareness Day! 🎉 Check out our website for the official proclamation and press release on this landmark event. Visit 🔗 gaapp.org/wccd2024/ to learn more. Global Allergy & Airways Patient Platform #ChronicCoughDay